2017
Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients
Stern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, Hinchcliff M, Brenner DM. Abnormal esophageal acid exposure on high‐dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterology & Motility 2017, 30 PMID: 29110377, PMCID: PMC5771836, DOI: 10.1111/nmo.13247.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsAcid exposure timeEsophageal acid exposureSystemic sclerosis patientsHigh-dose proton pump inhibitorsEsophageal pH-impedance testingGastro-esophageal reflux diseasePH-impedance testingSSc patientsSystemic sclerosisSclerosis patientsAcid exposurePPI therapyHigh-dose proton pump inhibitor therapyAbnormal esophageal acid exposureCase-control retrospective analysisHigh-dose PPI therapyHigher acid exposure timeHigh-resolution manometry findingsTotal acid exposure timeProton pump inhibitor therapyTwice-daily proton pump inhibitorsHiatal hernia sizeNon-SSc patientsRheumatology SSc criteria
2014
Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis
Carlson DA, Hinchcliff M, Pandolfino JE. Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. Current Rheumatology Reports 2014, 17: 475. PMID: 25475597, PMCID: PMC4343525, DOI: 10.1007/s11926-014-0475-y.Peer-Reviewed Original ResearchMeSH KeywordsEndoscopy, GastrointestinalEsophageal DiseasesEsophageal pH MonitoringGastroesophageal RefluxHumansManometryProton Pump InhibitorsScleroderma, SystemicConceptsSystemic sclerosisEsophageal diseaseAbnormal esophageal acid exposureGastroesophageal reflux disease treatmentSymptoms of heartburnEsophageal acid exposureProton pump inhibitorsEsophageal dysmotilityPump inhibitorsGERD managementObjective findingsReflux monitoringClinical characterizationEndoscopic ultrasoundAcid exposureImpedance planimetryDiagnostic testingDiseaseDisease treatmentSclerosisPatientsTreatmentDysmotilityHeartburnDysphagia
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification